Obagi Medical, a prominent player in physician-dispensed skincare, has presented new clinical data regarding its innovative hyaluronic acid injectables and Nu-Cil scalp treatment. This announcement, made on November 16, 2025, coincided with the American Society for Dermatologic Surgery (ASDS) Annual Meeting held from November 13 to 16 in Chicago, Illinois. The findings highlight the effectiveness of Obagi’s hyaluronic acid fillers, which were recognized as one of the top ten abstracts presented at the conference.
The pivotal study compared two hyaluronic acid fillers specifically designed for midface augmentation. According to the research, these fillers significantly improve the appearance of nasolabial folds, which are the lines that run from the nose to the corners of the mouth. This comparison, led by renowned dermatologist Dr. Sue Ellen Cox, underscores the advancements in aesthetic solutions that can provide lasting results for patients seeking facial rejuvenation.
The ASDS Annual Meeting is a key event in the dermatology calendar, attracting leading experts in the field to discuss the latest advancements in skin care and cosmetic procedures. Obagi Medical’s participation signifies its commitment to staying at the forefront of innovation within the aesthetic industry. The recognition of their abstract further solidifies their reputation for excellence in research and product development.
In addition to the hyaluronic acid injectables, Obagi Medical also showcased its Nu-Cil scalp treatment, which aims to improve hair health and support hair growth. The data presented indicates promising results, contributing to a comprehensive portfolio of products aimed at enhancing both skin and scalp conditions.
Obagi Medical’s affiliation with Waldencast plc (NASDAQ: WALD) enhances its capability to deliver high-quality, physician-dispensed skincare solutions. The company continues to invest in research and development, focusing on delivering effective and scientifically backed products to healthcare professionals and their patients.
The findings shared at the ASDS meeting are expected to have a significant impact on dermatological practices and patient outcomes, as healthcare providers become more informed about the latest advancements in treatment options. This new data is likely to encourage more practitioners to consider Obagi’s solutions in their treatment plans.
As the aesthetics industry evolves, the emphasis on clinical data and proven results remains paramount. Obagi Medical’s commitment to scientific research and innovation positions it as a leader in the field, ensuring that patients receive safe and effective treatments that meet their aesthetic needs.
With the continuous evolution of cosmetic dermatology, events like the ASDS Annual Meeting play a crucial role in disseminating important information and fostering collaboration among professionals. Obagi Medical’s contributions to this dialogue reflect its dedication to advancing the science of skincare and enhancing the overall patient experience.
